What Happened?
Shares of genomics company Pacific Biosciences of California (NASDAQ: PACB) jumped 9.3% in the morning session after the National Institute on Aging's Long Life Family Study (LLFS) selected its technology to generate comprehensive genomic data.
The study planned to use PacBio's Revio systems to analyze data from as many as 7,800 participants. This major research effort was designed to shed light on why longevity runs in families and what factors contribute to healthier aging. The selection served as a significant endorsement of the company's long-read sequencing solutions. This news followed a separate positive announcement from the previous trading day regarding an expanded partnership with seqWell, a provider of genomic workflow solutions, which had already contributed to positive investor sentiment.
Is now the time to buy PacBio? Access our full analysis report here.
What Is The Market Telling Us
PacBio’s shares are extremely volatile and have had 79 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
PacBio is down 15.8% since the beginning of the year, and at $1.52 per share, it is trading 42.8% below its 52-week high of $2.65 from November 2024. Investors who bought $1,000 worth of PacBio’s shares 5 years ago would now be looking at an investment worth $119.05.
Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.
